Dabrafenib, trametinib & neoadjuvant pembrolizumab in anaplastic thyroid cancer скачать в хорошем качестве

Dabrafenib, trametinib & neoadjuvant pembrolizumab in anaplastic thyroid cancer

Mark Zafereo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II trial of neoadjuvant pembrolizumab with dabrafenib and trametinib (DTP) in patients with BRAF V600E–mutated anaplastic thyroid cancer. This approach enabled a high rate of complete or near-complete resections, with many patients achieving a complete pathologic response. Progression-free and overall survival outcomes were improved compared to historical controls. Safety was manageable, though serious adverse events occurred. These results support DTP as a new standard of care in this setting. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.